Your journey to publication continues here Discover why


  • Product nameAnti-Met (c-Met) antibody
    See all Met (c-Met) primary antibodies
  • Description
    Rabbit polyclonal to Met (c-Met)
  • Specificityab63347 detects endogenous levels of total Met (c-Met) protein.
  • Tested applicationsELISA, ICC/IF, WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic non phosphopeptide derived from human Met (c-Met) around the phosphorylation site of tyrosine 1003 (V-D-YP-R-A).

  • Positive control
    • WB: HepG2 cell extracts. ICC/IF: A549 cells.



Our Abpromise guarantee covers the use of ab63347 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA 1/5000.
ICC/IF 1/500 - 1/1000.
WB 1/500 - 1/1000. Predicted molecular weight: 156 kDa.


  • FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
  • Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
    Note=Defects in MET may be associated with gastric cancer.
    Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
    Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
    Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
    Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
  • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
    Contains 3 IPT/TIG domains.
    Contains 1 protein kinase domain.
    Contains 1 Sema domain.
  • DomainThe kinase domain is involved in SPSB1 binding.
  • Post-translational
    Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
  • Cellular localizationMembrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • AUTS9 antibody
    • c met antibody
    • D249 antibody
    • Hepatocyte growth factor receptor antibody
    • HGF antibody
    • HGF receptor antibody
    • HGF/SF receptor antibody
    • HGFR antibody
    • MET antibody
    • Met proto oncogene tyrosine kinase antibody
    • MET proto oncogene, receptor tyrosine kinase antibody
    • Met proto-oncogene (hepatocyte growth factor receptor) antibody
    • Met proto-oncogene antibody
    • Met protooncogene antibody
    • MET_HUMAN antibody
    • Oncogene MET antibody
    • Par4 antibody
    • Proto-oncogene c-Met antibody
    • RCCP2 antibody
    • Scatter factor receptor antibody
    • SF receptor antibody
    • Tyrosine-protein kinase Met antibody
    see all

Anti-Met (c-Met) antibody images

  • ab63347, at 1/500 dilution, staining Met (c-Met) in A549 cells by Immunofluorescence, in the absence (left image) or presence (right image) of the immunising peptide.
  • All lanes : Anti-Met (c-Met) antibody (ab63347) at 1/500 dilution

    Lane 1 : HepG2 cell extracts
    Lane 2 : HepG2 cell extracts with immunising peptide at 10 µg

    Lysates/proteins at 30 µg per lane.

    Predicted band size : 156 kDa
    Observed band size : 156 kDa
    Additional bands at : 90 kDa. We are unsure as to the identity of these extra bands.

References for Anti-Met (c-Met) antibody (ab63347)

This product has been referenced in:
  • Vogel S  et al. Activated platelets interfere with recruitment of mesenchymal stem cells to apoptotic cardiac cells via high mobility group box 1/Toll-like receptor 4-mediated down-regulation of hepatocyte growth factor receptor MET. J Biol Chem 289:11068-82 (2014). ICC/IF ; Human . Read more (PubMed: 24567328) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab63347.
Please use the links above to contact us or submit feedback about this product.